Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators

Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology
David SchwartzmanDavid E Euler

Abstract

Previous studies have demonstrated that ambulatory atrial defibrillation shocks delivered by an implantable cardioverter-defibrillator (ICD) are safe and effective, but poorly tolerated. Separate studies have demonstrated the utility of single oral bolus propafenone for conversion of recent-onset atrial fibrillation (AF); however, most patients were hospitalized, had no structural heart disease, were taking no other antiarrhythmic drugs, and were not exposed to concomitant shock. We hypothesized that a single oral bolus dose of propafenone given early after onset would be a safe and effective adjunct to ICD-based AF therapy and improve overall therapy tolerance. A randomized three-way crossover study design was used to compare three strategies, deployed in the ambulatory setting early after AF episode onset in 35 ICD patients with advanced, drug refractory episodic/persistent syndromes, many of whom had structural heart disease and were taking other antiarrhythmic drugs: (i) single oral bolus propafenone (600 mg), followed by ICD shock if necessary; (ii) single oral bolus placebo, followed by ICD shock if necessary; and (iii) no oral bolus therapy and ICD shock if necessary (no bolus). Antiarrhythmic efficacy, defined by the re...Continue Reading

References

Jan 1, 1993·Clinical Pharmacology and Therapeutics·M R UjhelyiM S Chow
Jun 2, 2001·Journal of Cardiovascular Electrophysiology·W SchoelsUNKNOWN Worldwide Jewel AF Investigators
Aug 29, 2001·Circulation·P A FriedmanS C Hammill
Jan 5, 2002·Journal of Cardiovascular Electrophysiology·M R GoldUNKNOWN Worldwide Jewel AF-Only Investigators
May 30, 2002·Journal of Cardiovascular Electrophysiology·Charles D SwerdlowUNKNOWN Worldwide Model 7250 AF-Only Investigators
Jul 10, 2002·Journal of the American College of Cardiology·David SchwartzmanEduardo N Warman
Nov 26, 2003·The American Journal of Cardiology·Alessandro CapucciMassimo F Piepoli
Dec 3, 2004·The New England Journal of Medicine·Paolo AlboniGermano Gaggioli

❮ Previous
Next ❯

Citations

Jul 14, 2010·Pharmacology & Therapeutics·Ursula Ravens
Mar 21, 2007·Pacing and Clinical Electrophysiology : PACE·Giuseppe BorianiAngelo Branzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.